Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | +2.75% | +1.82% | +103.64% |
04-19 | Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says | MT |
04-01 | Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Sales 2024 * | 7.5M 10.25M | Sales 2025 * | 18.75M 25.63M | Capitalization | 40.23M 54.99M |
---|---|---|---|---|---|
Net income 2024 * | -67M -91.58M | Net income 2025 * | -72M -98.41M | EV / Sales 2024 * | -20.8 x |
Net cash position 2024 * | 196M 268M | Net cash position 2025 * | 302M 412M | EV / Sales 2025 * | -13.9 x |
P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-0.9
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.09% |
Latest transcript on Xilio Therapeutics, Inc.
1 day | +2.75% | ||
1 week | +1.82% | ||
Current month | +3.70% | ||
1 month | -26.80% | ||
3 months | +67.41% | ||
6 months | -46.67% | ||
Current year | +103.64% |
Managers | Title | Age | Since |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 19-05-21 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 22-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 20-07-22 |
Daniel Curran
BRD | Director/Board Member | 57 | 20-11-30 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 22-09-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 1.12 | +2.75% | 28 327 |
24-04-26 | 1.09 | +7.92% | 144,163 |
24-04-25 | 1.01 | -4.72% | 239,428 |
24-04-24 | 1.06 | +0.95% | 297,031 |
24-04-23 | 1.05 | -4.55% | 448,445 |
Delayed Quote Nasdaq, April 29, 2024 at 09:59 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+103.64% | 40.23M | |
+2.05% | 42.75B | |
+47.70% | 41.61B | |
+11.55% | 41.34B | |
-12.36% | 26.59B | |
+8.07% | 25.49B | |
-23.87% | 18.12B | |
+29.63% | 12.24B | |
-1.98% | 11.76B | |
+7.89% | 11B |
- Stock Market
- Equities
- XLO Stock